Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px
Document › Details

OSE Immunotherapeutics S.A.. (8/31/17). "Press Release: OSE Immunotherapeutics Announces Presentation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 2017". Nantes.

Organisations Organisation OSE Immunotherapeutics S.A.
  Today OSE Pharma S.A.
  Group OSE Immunotherapeutics (Group)
  Organisation 2 Rodman & Renshaw Conferences LLC
Products Product Rodman & Renshaw Annual Global Investment Conference 2017 New York
  Product 2 Tedopi® cancer immunotherapy
Index term Index term OSE Immunotherapeutics–Rodman & Renshaw: investor conference, 201709 supply service OSE presents at Rodman & Renshaw Global Investment Conference
Persons Person Costantini, Dominique (OSE Pharma 201504 CEO + Co-founder + former CEO + Co-founder of BioAlliance Pharma in 1997)
  Person 2 Maggos, Chris (LifeSci Advisors 201511 Managing Director Europe before Addex 201106–201302 BusDev + Communication)
     


OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.

Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: 19th Annual Rodman & Renshaw Global Investment Conference
Day: Monday, September 11, 2017
Time: 12:30 – 12:55 PM (Eastern Time)
Place: Holmes II; Lotte New York Palace Hotel, New York City

The presentation will be webcast live. To access the webcast, please visit: http://wsw.com/webcast/rrshq27/ose or the company’s website: http://ose-immuno.com/. The webcast replay will remain available for 90 days following the live presentation.


ABOUT OSE IMMUNOTHERAPEUTICS

Our ambition is to become a world leader in activation and regulation immunotherapies OSE Immunotherapeutics is a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.

The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical phase 3 registration trials to R&D:

In immuno-oncology:

> Tedopi®, a combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology –
Continuation of the registration Phase 3 trial in advanced NSCLC in already included HLA A2+ patients EU /US -Orphan Status in the US - A Phase 2 with Tedopi® in combination with a checkpoint inhibitor is considered in a cancer indication of interest.

>OSE-172 (Effi-DEM), new generation checkpoint inhibitor targeting the SIRP-a receptor - In preclinical development for several cancer models.

> OSE-703 (Effi-3), cytotoxic monoclonal antibody against the alpha chain of IL-7R - Under a multi-year strategic research collaboration with Memorial Sloan Kettering Cancer Center, New York.

In auto-immune diseases and transplantation:

> FR104, CD28-antagonist in immunotherapy - Phase 1 trial completed – For the treatment of autoimmune diseases and for use with transplantation - Licensed to Janssen Biotech Inc. to pursue clinical development.

> OSE-127 (Effi-7), interleukin receptor-7 antagonist - In preclinical development for inflammatory bowel diseases and other autoimmune diseases. License option agreement with Servier for the development and commercialization.


The portfolio’s blockbuster potential gives OSE Immunotherapeutics the ability to enter global agreements at different stages of development with major pharmaceutical players.

Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at $67 billion in 2018 **.

There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales towards $10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.


* Citi Research Equity
** BCC Research

Click and follow us on Twitter and Linkedln


Contacts

OSE Immunotherapeutics
Sylvie Détry
sylvie.detry@ose-immuno.com
+33 143 297 857

Media: LifeSci Public Relations
Matt Middleman, M.D.
matt.middleman@lifescipublicrelations.com
+1 646 627 8384
Investors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254


Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import.

Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.

This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 28 April 2017 under the number R.17-038, including the annual financial report for the fiscal year 2016, available on the OSE Immunotherapeutics’ website.

Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

   
Record changed: 2017-09-21

Advertisement

Picture [LSF] Life-Sciences-France.com – The Business Web Portal 600x80px

More documents for OSE Immunotherapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px